KCA
Search
- Page Path
- HOME > Search
Original Articles
- Young Age Is Associated with Increased Locoregional Recurrence in Node-Positive Breast Cancer with Luminal Subtypes
- Sang-Won Kim, Mison Chun, Sehwan Han, Yong Sik Jung, Jin Hyuk Choi, Seok Yun Kang, Hyunee Yim, Seung Hee Kang
- Cancer Res Treat. 2017;49(2):484-493. Published online August 23, 2016
- DOI: https://doi.org/10.4143/crt.2016.246
-
Abstract
PDF
PubReader
ePub - Purpose
The effects of biological subtypes within breast cancer on prognosis are influenced by age at diagnosis. We investigated the association of young age with locoregional recurrence (LRR) between patients with luminal subtypes versus those with nonluminal subtypes.
Materials and Methods
Medicalrecords of 524 breast cancer patientswith positive lymph nodes between 1999 and 2010 were reviewed retrospectively. All patients received curative surgery and adjuvant chemotherapy based on contemporary guidelines. Radiation was delivered for patients who underwent breast conserving surgery or those who had four or more positive lymph nodes after mastectomy. Adjuvant hormone therapywas administered to 413 patientswith positive hormone receptors according to their menstrual status.
Results
During median follow-up of 84 months, the 10-year locoregional recurrence-free survival rate (LRRFS) was 84.3% for all patients. Patients < 40 years showed significantly worse 10-year LRRFS than those ≥ 40 years (73.2% vs. 89.0%, respectively; p=0.01). The negative effect of young age on LRRFS was only observed in luminal subtypes (69.7% for < 40 years vs. 90.8% for ≥ 40 years; p < 0.01). Multivariate analysis using luminal subtypes ≥ 40 years as a reference revealed luminal subtypes < 40 years were significantly associated with increased risk of LRR (hazard ratio, 2.33; p < 0.01).
Conclusion
Young breast cancer patients with positive lymph nodes had a higher risk of LRR than those aged ≥ 40 years. This detrimental effect of young age on LRR was confined in luminal subtypes. -
Citations
Citations to this article as recorded by
- Treatment, toxicity, and mortality after subsequent breast cancer in female survivors of childhood cancer
Cindy Im, Hasibul Hasan, Emily Stene, Sarah Monick, Ryan K. Rader, Jori Sheade, Heather Wolfe, Zhanni Lu, Logan G. Spector, Aaron J. McDonald, Vikki Nolan, Michael A. Arnold, Miriam R. Conces, Chaya S. Moskowitz, Tara O. Henderson, Leslie L. Robison, Greg
Nature Communications.2025;[Epub] CrossRef - The disparities in prognostic prediction and annualized hazard function in different molecular subtypes between young Chinese and White American women with breast cancer
Yuanyuan Zeng, Jun Wang, Xiaorong Zhong, Zhongzheng Xiang, Tian Yang, Siting Yu, Zelei Dai, Ningyue Xu, Lei Liu
Frontiers in Oncology.2023;[Epub] CrossRef - Comparing the Prognoses of Breast-Conserving Surgeries for Differently Aged Women with Early Stage Breast Cancer: Use of a Propensity Score Method
Shurui Bao, Guijin He, Pranshu Sahgal
The Breast Journal.2022; 2022: 1. CrossRef - The different prognostic impact of age according to individual molecular subtypes in breast cancer
Nam Hee Kim, Hye Won Bang, Yong Hwa Eom, Seung Hye Choi
Annals of Surgical Treatment and Research.2022; 103(3): 129. CrossRef - Do prognosis and clinicopathological features differ in young early-stage breast cancer?
Akif Enes Arikan, Halil Kara, Onur Dülgeroğlu, Esin Nur Erdoğan, Emir Capkinoglu, Cihan Uras
Frontiers in Surgery.2022;[Epub] CrossRef - Comparisons of breast conserving therapy versus mastectomy in young and old women with early-stage breast cancer: long-term results using propensity score adjustment method
Lize Wang, Yingjian He, Jinfeng Li, Tianfeng Wang, Yuntao Xie, Zhaoqing Fan, Tao Ouyang
Breast Cancer Research and Treatment.2020; 183(3): 717. CrossRef - The Prognostic Impact of Age at Diagnosis Upon Breast Cancer of Different Immunohistochemical Subtypes: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Analysis
Shibin Cai, Wenjia Zuo, Xunxi Lu, Zongchao Gou, Yi Zhou, Pengpeng Liu, Yin Pan, Shuzheng Chen
Frontiers in Oncology.2020;[Epub] CrossRef - Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy
Tae In Yoon, Ui-Kang Hwang, Eui Tae Kim, SaeByul Lee, Guiyun Sohn, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Seonok Kim, Sei Hyun Ahn, Hee Jeong Kim
Breast Cancer Research and Treatment.2017; 165(2): 311. CrossRef
- Treatment, toxicity, and mortality after subsequent breast cancer in female survivors of childhood cancer
- 11,952 View
- 295 Download
- 9 Web of Science
- 8 Crossref
- Effect of Oral Nutritional Support During Radiation Therapy in Patients with Thoracic and Gead/Neck Cancer
- Mi Sun Chun, Seung Hee Kang, Hye Kyung Kwon, Young Taek Oh, Joo Ri Kim, Hyun Joo Lee, Soon Young Lee, Sun Jeong Choi
- J Korean Cancer Assoc. 1998;30(4):781-789.
-
Abstract
PDF
- PURPOSE
This study was designed to evaluate the role of oral nutritional support and nutritional counseling by dietician during radiation therapy.
MATERIALS AND METHODS
This study included total 58 patients with head/neck, lung, or esophageal cancers who received radiation therapy with radical purpose between February and December, 1996. They were randomized either into nutrient supplement group (Group I) or control group (Group II). In Group I, the dietician advised patients to take high density nutrient supplement (NuCare, 250 kcal/can, Miwon co., LTD) based on dieticians initial evaluation for oral intake from initiation to completion of radiation therapy. In Group II, patients received nutritional support other than high density nutrient supplement only when patients lose weight more than 2 Kg during radiation treatment. All patients were evaluated for nutritional status and diet pattern and received nutritional counseling before radiation therapy and then weekly during treatment.
RESULTS
Total 45 patients (22 patients in group I, 23 patients in group II) were available. In group I, all patients received average 3 cans (2~4 cans) a day. The calory from nutrient supplement was 43.9% of their daily energy intake (25.9~68.7%). About 72.7% of patients in Group I could keep up with their oral intake over 80% of daily requirement energy comparing to only 12.3% for patients in Group II(p<0.05). The patients in Group I started to lose weight 2 weeks later and lost weight more than 3 Kg less often than patients in Group II (5/22 vs 8/23, p>0.05).
CONCLUSION
There was less significant weight loss in patients who started oral nutritional supplement based on the daily requirement energy early in radiation therapy. We think it is better to recommend nutritional supplement before weight loss started because radiation induced side effects such as esophagitis and oral mucositis prohibited patients to continue to take nutrient supplement.
- 3,191 View
- 35 Download
First
Prev
